Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapport TherapeuticsRAPP -1.80%14 3-Year Share Buyback Ratio is -10.50 as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,194 Biotechnology companies, Rapport Therapeutics ranks better than 52.01% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Rapport Therapeutics's current 3-Year Share Buyback Ratio was -10.50%.
The historical rank and industry rank for Rapport Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
RAPP'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -10.5 Med: -10.5 Max: -10.5
Current: -10.5
During the past 4 years, Rapport Therapeutics's highest 3-Year Share Buyback Ratio was -10.50%. The lowest was -10.50%. And the median was -10.50%.
RAPP's 3-Year Share Buyback Ratio is ranked better than 52.01% of 1194
companies
in the Biotechnology industry
Industry Median: -11.65
vs RAPP: -10.50
Rapport Therapeutics (NAS:RAPP) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Rapport Therapeutics 3-Year Share Buyback Ratio Related Terms
RAPP vs AUPH, PVLA, GLUE: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Rapport Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's 3-Year Share Buyback Ratio falls into.
Rapport Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -10.50 mean?
Rapport Therapeutics (RAPP) has a 3-Year Share Buyback Ratio of -10.50 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rapport Therapeutics and its competitors. According to the industry distribution chart, Rapport Therapeutics ranks #573 out of 1194 companies in the Biotechnology industry, placing it in the top 48%.
Is Rapport Therapeutics' 3-Year Share Buyback Ratio too high?
Rapport Therapeutics' current 3-Year Share Buyback Ratio is -10.50. Based on the distribution chart, Rapport Therapeutics ranks #573 out of 1194 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' 3-Year Share Buyback Ratio compare to AUPH and PVLA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #573 out of 1194 companies for 3-Year Share Buyback Ratio. This puts Rapport Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rapport Therapeutics and its competitors. Rapport Therapeutics's current 3-Year Share Buyback Ratio is -10.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current 3-Year Share Buyback Ratio of -10.50. The current 3-Year Share Buyback Ratio is -10.50. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current 3-Year Share Buyback Ratio is -10.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
